- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02167438
Reducing Cesarean Childbirth Rates Using the Hem-Avert Perianal Stabilizer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Women may sometimes be reluctant to push resulting in a prolonged second stage labor, which could lead to a Cesarean section. This study will record the frequency of Cesarean sections in two groups to determine if there are any measurable differences.
The investigational device in this study is the HEM-AVERT® Perianal Stabilizer manufactured by Stetrix, Inc. This device has received previous FDA clearance as a Class II device to prevent hemorrhoids during childbirth. This study is being conducted by Stetrix, Inc. and falls within the guidelines set forth by the Food and Drug Administration in 21 CFR Section 812.2 as a non-significant risk study. The HEM-AVERT® Perianal Stabilizer is a Class II device in accordance with FDA regulation 21 CFR 890.5765. The Class II version of the device and the investigational device are identical in terms of materials, design, intended population and area used. The sole difference is that data will be collected in order to support an application to the FDA to obtain clearance of the device for the specific claim of reducing the C-section rate and/or reducing the second stage of labor times. This difference in data collection may be viewed as off-label use of the device although there is no new risk to the subject in the use of this device as an investigational device.
The primary objective of this study is to reduce the C-section rate and/or the second stage of labor times while using this device. For patients scheduled for a vaginal delivery, success is defined as completing the vaginal delivery process.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Saint Francis Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant women between the ages of 18 and 40 years old at the time of enrollment
- Gestational age between 34 and 42 weeks at the time of enrollment
- Live singleton gestation
- Candidate for vaginal delivery.
- Willing and able to comply with the study plan as indicated by understanding and signing the subject informed consent form
Exclusion Criteria:
- Subject unable to speak English
- Subject unable to understand and sign the informed consent form
- Delivery planned outside the clinical center
- Subject is scheduled for vaginal delivery with anticipated complications (i.e. including but not limited to non-vertex presentation or macrosomia >4,000 grams)
- Subject scheduled for an elective cesarean birth
- Preeclampsia with severe features, eclampsia, HELLP syndrome
- Multiple Gestation
- PROM (premature rupture of membranes)
- Previous Cesarean Section
- PTL (preterm labor)
- Known major fetal anomaly or fetal demise.
- Suspected or proven chorioamnionitis
- Placenta previa
- Maternal insulin dependent diabetes
- Maternal health conditions deemed as risk factors by investigators such as renal or cardiopulmonary disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational
Application of the Hem-Avert device.
|
|
No Intervention: Control
No Application of the Hem-Avert device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measuring the reduction in Cesarean section rates.
Time Frame: 12 Months
|
This study is a single-site, prospective, randomized, concurrently-controlled study.
Subjects will undergo screening to determine their enrollment eligibility.
All subjects who meet inclusion criteria will be offered participation in this study.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measuring the reduction of second-stage of labor times.
Time Frame: 12 Months
|
This is a single-site, prospective, randomized concurrently controlled study.
Subjects will undergo screening to determine their enrollment eligibility.
All subjects who meet inclusion criteria will be offered participation in the study.
|
12 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cesarean Section
-
Assiut UniversityNot yet recruitingCesarean Section Complications | Cesarean Section Niche
-
Recep Tayyip Erdogan University Training and Research...CompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Ataturk UniversityUnknownCesarean Section Complications | Cesarean Section; Complications, Wound, Dehiscence | Cesarean Section, Repeated | Cesarean, Uterine Scar Thickness | Cesarean, Residual Myometrial ThicknessTurkey
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Odense University HospitalHvidovre University Hospital; Smith & Nephew, Inc.; University of Southern Denmark and other collaboratorsCompletedSurgical Wound Infection | Cesarean Section; Dehiscence | Complications; Cesarean Section | Infection; Cesarean Section | Complications; Cesarean Section, Wound, Dehiscence | Wound; Rupture, Surgery, Cesarean SectionDenmark
-
Virginia Commonwealth UniversityRecruitingCesarean SectionUnited States
-
University Tunis El ManarCompleted
-
Federico II UniversityCompletedCesarean SectionItaly
-
Virginia Commonwealth UniversityCompletedCesarean SectionUnited States
-
University of CalgaryCompleted
Clinical Trials on Hem-Avert Perianal Stabilizer
-
Desert Perinatal AssociatesCompletedCesarean Section Rate
-
Stetrix, Inc.CompletedComplications; Cesarean SectionUnited States
-
Stetrix, Inc.Baptist Memorial Health Care CorporationCompleted